National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting, 38450 [E9-18529]

Download as PDF 38450 Federal Register / Vol. 74, No. 147 / Monday, August 3, 2009 / Notices page limitations. Submissions exceeding this limit will not be accepted and will be returned. Oral testimony of this material at the meeting will be limited to no more than 5–6 minutes in length. Because of time constraints for oral testimony, testifiers may not be able to present the complete information as it is contained in their written form submitted for inclusion in the public record for the meeting. Therefore, testifiers are requested to summarize the major points of emphasis from the written testimony, not to exceed 6 minutes of oral testimony. Those individuals or organizations that have indicated they will present oral testimony at the meeting in Providence will be notified prior to the meeting regarding the approximate time for their oral presentation. Individuals and organizations wishing to provide written statements only should send a copy of their statements, electronically or by mail, to the above Web site or address by September 13, 2009. Written testimony received by that date will be made available at the September 21–23 meeting. Logistics questions related to this meeting should be addressed to Ms. Jory Barone at ESI, while program-specific questions should be addressed to Ms. Maureen Pearlman at the Warren Alpert Medical School of Brown University, Providence, Rhode Island, 401–276– 7800, ext. 123, mpearlman@wihri.org. At the conclusion of the regional meetings, the ORWH will hold a meeting at the NIH to summarize the deliberations from the regional conferences. The resulting report to the ORWH and the NIH will ensure that women’s health research in the coming decade continues to support a vigorous research agenda incorporating the latest advances in technology and cuttingedge science. Dated: July 28, 2009. Raynard S. Kington, Acting Director, National Institutes of Health. [FR Doc. E9–18535 Filed 7–31–09; 8:45 am] The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: President’s Cancer Panel. Date: September 22, 2009. Time: 8 a.m. to 4:10 p.m. Agenda: America’s Demographic and Cultural Transformation: Implications for the Cancer Enterprise. Place: The Westin Seattle, 1900 Fifth Avenue, Seattle, WA 98101. Contact Person: Abby B. Sandler, PhD, Executive Secretary, Chief, Institute Review Office, Office of the Director, 6116 Executive Blvd., Suite 220, MSC 8349, National Cancer Institute, NIH, Bethesda, MD 20892–8349. (301) 451–9399. sandlera@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 28, 2009. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–18531 Filed 7–31–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–P National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES sroberts on DSKD5P82C1PROD with NOTICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the President’s Cancer Panel. VerDate Nov<24>2008 16:05 Jul 31, 2009 Jkt 217001 National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council for Biomedical Imaging and Bioengineering. The meeting will be open to the public as indicated below, with attendance limited to space available. PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Biomedical Imaging and Bioengineering. NACBIB, September 2009. Date: September 11, 2009. Open: 9 a.m. to 1 p.m. Agenda: Report from the Institute Director, other Institute Staff and presentations of working group reports. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Closed: 1 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Anthony Demsey, PhD, Director, National Institute of Biomedical Imaging, and Bioengineering, 6701 Democracy Boulevard, Room 241, Bethesda, MD 20892. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// www.nibib1.nih.gov/about/NACBIB/ NACBIB.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.701, ARRA Related Biomedical Research and Research Support Awards. National Institutes of Health, HHS) Dated: July 28, 2009. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–18529 Filed 7–31–09; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\03AUN1.SGM 03AUN1

Agencies

[Federal Register Volume 74, Number 147 (Monday, August 3, 2009)]
[Notices]
[Page 38450]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-18529]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Biomedical Imaging and Bioengineering; 
Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
National Advisory Council for Biomedical Imaging and Bioengineering.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Advisory Council for Biomedical 
Imaging and Bioengineering. NACBIB, September 2009.
    Date: September 11, 2009.
    Open: 9 a.m. to 1 p.m.
    Agenda: Report from the Institute Director, other Institute 
Staff and presentations of working group reports.
    Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, 
Bethesda, MD 20817.
    Closed: 1 p.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications and/or 
proposals.
    Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, 
Bethesda, MD 20817.
    Contact Person: Anthony Demsey, PhD, Director, National 
Institute of Biomedical Imaging, and Bioengineering, 6701 Democracy 
Boulevard, Room 241, Bethesda, MD 20892.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: https://www.nibib1.nih.gov/about/NACBIB/NACBIB.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.701, ARRA 
Related Biomedical Research and Research Support Awards. National 
Institutes of Health, HHS)

    Dated: July 28, 2009.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-18529 Filed 7-31-09; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.